HC Wainwright Comments on Clene’s Q1 Earnings (NASDAQ:CLNN)

Clene Inc. (NASDAQ:CLNN) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Clene in a research note issued on Monday, March 24th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($1.11) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $31.00 target price on the stock. The consensus estimate for Clene’s current full-year earnings is ($5.19) per share. HC Wainwright also issued estimates for Clene’s Q2 2025 earnings at ($1.15) EPS, Q3 2025 earnings at ($1.28) EPS, Q4 2025 earnings at ($1.35) EPS, FY2025 earnings at ($4.92) EPS, FY2026 earnings at ($3.02) EPS and FY2027 earnings at $0.52 EPS.

Clene (NASDAQ:CLNN) last released its quarterly earnings results on Monday, March 24th. The company reported ($1.67) earnings per share for the quarter, missing the consensus estimate of ($1.21) by ($0.46). Clene had a negative net margin of 8,556.77% and a negative return on equity of 1,106.30%. The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.13 million.

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Clene in a report on Monday. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Clene has a consensus rating of “Buy” and a consensus target price of $55.25.

Clene Trading Up 2.3 %

Shares of NASDAQ CLNN opened at $3.54 on Wednesday. The firm has a market cap of $29.47 million, a P/E ratio of -0.67 and a beta of 0.27. The business’s 50 day moving average is $4.49 and its 200-day moving average is $4.88. Clene has a 1-year low of $3.37 and a 1-year high of $9.20.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. SBI Securities Co. Ltd. bought a new stake in shares of Clene in the fourth quarter valued at approximately $69,000. Fullcircle Wealth LLC acquired a new position in Clene in the 4th quarter valued at $69,000. Renaissance Technologies LLC bought a new stake in shares of Clene during the 4th quarter valued at $96,000. Parsons Capital Management Inc. RI acquired a new stake in shares of Clene during the 4th quarter worth $194,000. Finally, Geode Capital Management LLC increased its position in shares of Clene by 52.9% in the fourth quarter. Geode Capital Management LLC now owns 65,112 shares of the company’s stock worth $346,000 after purchasing an additional 22,539 shares during the period. 23.28% of the stock is owned by institutional investors.

Clene Company Profile

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.